Monday, October 3, 2022


Biotechnology News Magazine

Isaac Klein MD PhD Appointed Chief Scientific Officer Dewpoint Therapeutics: Effective May 3, 2021

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Isaac Klein MD PhD is a physician-scientist and medical oncologist at the Dana-Farber Cancer Institute Breast Oncology Center and has published extensively on the role of condensates in cancer.

“Isaac is a brilliant scientific mind who is well poised to lead our research and clinical development organization as we embark on our next phase of growth as a company,” said Ameet Nathwani, M.D., Chief Executive Officer of Dewpoint Therapeutics. “As a breast cancer specialist and accomplished researcher, he epitomizes the bench-to-bedside understanding of patients that we value as an organization. His expertise and intense interest in the meeting point between biomolecular condensates and disease will prove invaluable as we advance all our programs toward the clinic as well as deepen our focus in cancer.”

Previously, Dr. Klein was a researcher in the Rick Young lab at the Whitehead Institute of the Massachusetts Institute of Technology. His research focuses on understanding the role of condensates in cancer, transcription, and drug activity. As a physician, Dr. Klein has cared for patients with both early and metastatic breast cancer, with an interest in novel therapies and personalized treatment.

Dr. Klein earned an undergraduate degree from Cornell University and holds a Ph.D. in biology from The Rockefeller University and an M.D. from Weill Cornell Medical College. He trained in Internal Medicine at the Brigham and Women’s Hospital of Harvard University, and in Medical Oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital.

“I am passionate about developing novel therapies for patients living with cancer and other devastating diseases,” said Dr. Klein. “As a leader in condensate biology, and home to many of the field’s pioneering scientists, Dewpoint is uniquely positioned to understand, explore, and develop a range of drugs that exploit the role of condensates in disease. I’m thrilled to lead Dewpoint’s research and development as we work to translate condensate biology into drugs that impact human health across a broad range of diseases.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine